ImmunityBio to Host Conference Call on March 3, 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy IBRX?
Source: Newsfilter
- Conference Call Details: ImmunityBio will host a conference call on March 3, 2026, at 1:30 PM PT to provide a business update and review 2025 financial results, reflecting the company's commitment to transparency and investor communication.
- Clinical Trial Progress: The call will cover advancements in the company's clinical trial pipeline, indicating ImmunityBio's ongoing innovation and R&D efforts in immunotherapies for cancer and infectious diseases, which may impact future market competitiveness.
- Investor Access: Investors can join the call via the company's Investor Relations website or by dialing specified numbers, emphasizing the company's focus on enhancing investor experience by encouraging timely participation.
- Replay Availability: A replay of the call will be available on the Investor Relations website for at least 90 days post-event, increasing information accessibility and transparency for stakeholders.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IBRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IBRX
Wall Street analysts forecast IBRX stock price to fall
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 10.440
Low
5.00
Averages
7.33
High
9.00
Current: 10.440
Low
5.00
Averages
7.33
High
9.00
About IBRX
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ImmunityBio Set to Announce Q4 Earnings with Mixed Estimates
- Earnings Announcement Date: ImmunityBio is set to release its Q4 earnings on March 3rd after market close, with market participants keenly awaiting its financial performance amid a competitive biopharmaceutical landscape.
- Earnings Expectations: The consensus EPS estimate stands at -$0.08, indicating ongoing challenges in profitability that could affect investor confidence in the stock.
- Revenue Projections: The consensus revenue estimate is $44.77 million, reflecting a substantial year-over-year growth of 521.8%, which highlights significant market demand but may raise concerns due to high base effects.
- Estimate Revision Trends: Over the past three months, there have been no upward revisions for EPS or revenue estimates, with one downward revision each, suggesting analysts' cautious outlook on the company's future performance, potentially impacting stock price movements.
See More
S&P 500 Futures Hold Steady in Pre-Market Session; Moderna and SSR Mining Take the Lead
- Market Opening: U.S. stock markets are set to open in two hours.
- Moderna Inc. Performance: Moderna Inc. (MRNA) saw an 11.0% increase in pre-market trading.
- SSR Mining Inc. Performance: SSR Mining Inc. (SSRM) experienced a 9.2% rise in pre-market trading.
- Overall Market Sentiment: The pre-market gains indicate positive sentiment among investors for these companies.
See More
Wall Street Declines as Oil Prices Surge Amid Middle East Tensions
- Market Volatility: Wall Street closed lower on Tuesday, with the S&P 500 down 0.9% and the Nasdaq sliding 1%, reflecting investor concerns over potential disruptions to energy supplies amid escalating tensions in the Middle East.
- Surge in Oil Prices: Both Brent and WTI crude oil prices jumped over 4.5%, with Brent rising more than 12% over two sessions, indicating that geopolitical risks are driving significant volatility in global energy markets.
- Trump's Intervention: President Trump announced that the U.S. would provide insurance guarantees and potentially naval escorts for vessels transiting the Strait of Hormuz, aiming to ensure the continued flow of energy, highlighting the U.S.'s critical role in global energy security.
- Investor Sentiment Turns Bearish: Retail sentiment towards the SPDR S&P 500 ETF Trust and Invesco QQQ Trust shifted to 'bearish', reflecting market unease about future economic prospects, particularly in light of rising oil prices and instability in the Middle East.
See More
ImmunityBio Faces Severe Bladder Cancer Therapy Shortage
- Bladder Cancer Therapy Shortage: ImmunityBio highlighted a “terrible” shortage of the standard bladder cancer therapy BCG, with Merck as the sole global supplier, potentially delaying patient treatments and impacting the company's market share.
- Anktiva Launch in Saudi Arabia: The company is ready to ship Anktiva to Saudi Arabia following two approvals from the Saudi FDA, and despite escalating geopolitical tensions in the region, ImmunityBio remains committed to expanding its immunotherapy offerings in this market.
- Improved Financial Performance: ImmunityBio reported a net loss of $351.4 million for FY25, narrowing from $413.6 million the previous year, with product revenue reaching $113 million, up 700%, indicating a significant increase in clinical adoption of Anktiva.
- Recombinant BCG Initiative: The company emphasized its recombinant BCG program as a potential solution to the BCG shortage, with the FDA authorizing an expanded access program in February 2025, enrolling 580 patients to date, showcasing ImmunityBio's proactive approach to market challenges.
See More
ImmunityBio Earnings Preview and Market Reaction
- Earnings Expectations: ImmunityBio is projected to report FY2025 revenue of $113.3 million, a staggering 700% increase from $14.8 million in 2024, while losses per share are expected to improve to $0.38, indicating significant progress in its commercialization efforts.
- Anktiva's Strong Performance: Anktiva generated $113 million in net product revenue for 2025, marking a 700% year-over-year increase, with Q4 revenue soaring 431% to $38.3 million, surpassing market expectations and reflecting robust demand in the market.
- Promotion of IL-15 Mechanism: Founder Soon-Shiong has highlighted Anktiva's IL-15 mechanism in media appearances, emphasizing its potential in cancer treatment, particularly in combination with Merck's Keytruda, which may enhance efficacy and improve cancer-free rates for patients.
- Optimistic Market Sentiment: On Stocktwits, retail sentiment for IBRX has turned 'bullish' amid a 185% surge in message volume over 24 hours, with investors expressing optimistic price predictions that could drive the stock price rapidly upward, with some users forecasting it could reach $20.
See More
Top Performing Healthcare Stocks in March 2026
- ImmunityBio's Stellar Performance: ImmunityBio (IBRX) leads the healthcare sector with a remarkable 64.37% stock price increase over the past month, highlighting its strong growth potential in the biotechnology field.
- DaVita's Strong Rating: Following closely, DaVita (DVA) achieved a 48.00% gain and boasts a Quant Rating of 4.80, earning a Strong Buy recommendation, indicating robust market confidence in its future performance.
- Diverse Healthcare Sectors: The rankings encompass various industries including Biotechnology, Health Care Facilities, Health Care Services, Pharmaceuticals, and Health Care Equipment, showcasing a wide array of investment opportunities that attract diverse investor interest.
- Other Strong Performers: The Ensign Group (ENSG) and McKesson (MCK) posted gains of 24.52% and 18.36% respectively, further demonstrating the resilience and growth potential of the healthcare sector in the current market environment.
See More
ImmunityBio Set to Announce Q4 Earnings with Mixed Estimates
- Earnings Announcement Date: ImmunityBio is set to release its Q4 earnings on March 3rd after market close, with market participants keenly awaiting its financial performance amid a competitive biopharmaceutical landscape.
- Earnings Expectations: The consensus EPS estimate stands at -$0.08, indicating ongoing challenges in profitability that could affect investor confidence in the stock.
- Revenue Projections: The consensus revenue estimate is $44.77 million, reflecting a substantial year-over-year growth of 521.8%, which highlights significant market demand but may raise concerns due to high base effects.
- Estimate Revision Trends: Over the past three months, there have been no upward revisions for EPS or revenue estimates, with one downward revision each, suggesting analysts' cautious outlook on the company's future performance, potentially impacting stock price movements.
See More
S&P 500 Futures Hold Steady in Pre-Market Session; Moderna and SSR Mining Take the Lead
- Market Opening: U.S. stock markets are set to open in two hours.
- Moderna Inc. Performance: Moderna Inc. (MRNA) saw an 11.0% increase in pre-market trading.
- SSR Mining Inc. Performance: SSR Mining Inc. (SSRM) experienced a 9.2% rise in pre-market trading.
- Overall Market Sentiment: The pre-market gains indicate positive sentiment among investors for these companies.
See More
Wall Street Declines as Oil Prices Surge Amid Middle East Tensions
- Market Volatility: Wall Street closed lower on Tuesday, with the S&P 500 down 0.9% and the Nasdaq sliding 1%, reflecting investor concerns over potential disruptions to energy supplies amid escalating tensions in the Middle East.
- Surge in Oil Prices: Both Brent and WTI crude oil prices jumped over 4.5%, with Brent rising more than 12% over two sessions, indicating that geopolitical risks are driving significant volatility in global energy markets.
- Trump's Intervention: President Trump announced that the U.S. would provide insurance guarantees and potentially naval escorts for vessels transiting the Strait of Hormuz, aiming to ensure the continued flow of energy, highlighting the U.S.'s critical role in global energy security.
- Investor Sentiment Turns Bearish: Retail sentiment towards the SPDR S&P 500 ETF Trust and Invesco QQQ Trust shifted to 'bearish', reflecting market unease about future economic prospects, particularly in light of rising oil prices and instability in the Middle East.
See More
ImmunityBio Faces Severe Bladder Cancer Therapy Shortage
- Bladder Cancer Therapy Shortage: ImmunityBio highlighted a “terrible” shortage of the standard bladder cancer therapy BCG, with Merck as the sole global supplier, potentially delaying patient treatments and impacting the company's market share.
- Anktiva Launch in Saudi Arabia: The company is ready to ship Anktiva to Saudi Arabia following two approvals from the Saudi FDA, and despite escalating geopolitical tensions in the region, ImmunityBio remains committed to expanding its immunotherapy offerings in this market.
- Improved Financial Performance: ImmunityBio reported a net loss of $351.4 million for FY25, narrowing from $413.6 million the previous year, with product revenue reaching $113 million, up 700%, indicating a significant increase in clinical adoption of Anktiva.
- Recombinant BCG Initiative: The company emphasized its recombinant BCG program as a potential solution to the BCG shortage, with the FDA authorizing an expanded access program in February 2025, enrolling 580 patients to date, showcasing ImmunityBio's proactive approach to market challenges.
See More
ImmunityBio Earnings Preview and Market Reaction
- Earnings Expectations: ImmunityBio is projected to report FY2025 revenue of $113.3 million, a staggering 700% increase from $14.8 million in 2024, while losses per share are expected to improve to $0.38, indicating significant progress in its commercialization efforts.
- Anktiva's Strong Performance: Anktiva generated $113 million in net product revenue for 2025, marking a 700% year-over-year increase, with Q4 revenue soaring 431% to $38.3 million, surpassing market expectations and reflecting robust demand in the market.
- Promotion of IL-15 Mechanism: Founder Soon-Shiong has highlighted Anktiva's IL-15 mechanism in media appearances, emphasizing its potential in cancer treatment, particularly in combination with Merck's Keytruda, which may enhance efficacy and improve cancer-free rates for patients.
- Optimistic Market Sentiment: On Stocktwits, retail sentiment for IBRX has turned 'bullish' amid a 185% surge in message volume over 24 hours, with investors expressing optimistic price predictions that could drive the stock price rapidly upward, with some users forecasting it could reach $20.
See More
Top Performing Healthcare Stocks in March 2026
- ImmunityBio's Stellar Performance: ImmunityBio (IBRX) leads the healthcare sector with a remarkable 64.37% stock price increase over the past month, highlighting its strong growth potential in the biotechnology field.
- DaVita's Strong Rating: Following closely, DaVita (DVA) achieved a 48.00% gain and boasts a Quant Rating of 4.80, earning a Strong Buy recommendation, indicating robust market confidence in its future performance.
- Diverse Healthcare Sectors: The rankings encompass various industries including Biotechnology, Health Care Facilities, Health Care Services, Pharmaceuticals, and Health Care Equipment, showcasing a wide array of investment opportunities that attract diverse investor interest.
- Other Strong Performers: The Ensign Group (ENSG) and McKesson (MCK) posted gains of 24.52% and 18.36% respectively, further demonstrating the resilience and growth potential of the healthcare sector in the current market environment.
See More
